Eli Lilly's new oral obesity drug, Orforglipron, is gaining significant market share in the US, posing a competitive threat to Novo Nordisk's dominance.
Source Post
馃煝META & NOVO NORDISK: 驴C贸mo afectan las 脷LTIMAS NOTICIAS a nuestra VALORACI脫N?馃 |馃憠An谩lisis 2026Q3
Sep 27, 2026
The creator discusses Meta's recent surge of over 32% this month, driven by the launch of their AI agent "MUSE," which has shown promise in the consumer AI space and could generate billions in revenue. Despite high capital expenditures on data centers and AI, the market is now seeing potential returns, leading to a re-evaluation of Meta's valuation. Novo Nordisk's stock has declined 15% in the creator's fund.
Linked Mentions
Tickers discussed in this post
Wells Fargo raised its price target for Meta's stock following positive AI news.
J.P. Morgan is mentioned as having raised its valuation following news related to Meta's AI assistant.
Novo Nordisk's stock has declined 15% in the creator's fund, with the creator noting a decrease in net margin compared to the previous year.
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.